Sirtex Sponsors Educational Breakfast Lecture At The 2008 American College Of Radiation Oncology Annual Meeting
The lecture, hosted by Andrew S. Kennedy, M.D., F.A.C.R.O., co-medical director of Wake Radiology Oncology in Cary, N.C., is designed to update physicians on the latest clinical results regarding the use of microsphere therapy, including SIR-Spheres® microspheres, in the treatment of metastatic liver tumors. Sirtex manufactures SIR-Spheres microspheres, the only FDA-approved radioactive microspheres for treatment of metastatic liver tumors.1
"Sirtex is pleased to once again participate in this year's ACRO meeting," says Scott Richardson, director of sales for Sirtex. "There is a tremendous amount of research taking place involving SIR-Spheres microspheres, and meetings such as this provide a forum to distribute that information to physicians to help advance the role microsphere therapy can play in treating liver tumors."
The lecture is free and open to members of the medical community attending the ACRO meeting. No advanced reservations are required.
1 Sirtex Medical Inc.'s SIR-Spheres® microspheres are indicated for the treatment of non-resectable metastatic colorectal cancer in combination with intra-arterial FUDR chemotherapy. Information regarding other disease states or agents in combination with this device that is presented in peer-reviewed literature is different from the approved USA labeling for SIR-Spheres.
About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres microspheres
Selective Internal Radiation Therapy (SIRT) is a novel treatment for inoperable liver cancer that delivers high doses of radiation directly to the site of tumors. In a minimally-invasive treatment, millions of radioactive SIR-Spheres microspheres are infused via a catheter into the liver where they selectively target liver tumors with a dose of internal radiation up to 40 times higher than conventional radiotherapy, while sparing healthy tissue.
Clinical trials have confirmed that liver cancer patients treated with SIR-Spheres microspheres have response rates higher than with other forms of treatment, resulting in increased life expectancy, greater periods without tumor activity, and improved quality of life. SIRT has been found to shrink liver tumors more than chemotherapy alone.
SIRT using SIR-Spheres microspheres is approved for use in Australia, New Zealand, the United States of America (FDA approval), European Union (CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel and India. SIRT is available in 140 treatment centers around the world, and more than 6500 patients have been treated to date.
Approximately 90 physicians in the United States use Sirtex's SIR-Spheres microspheres in more than 86 medical centers.
http://www.sirtex.com
Sponsori Sirtex de învãþãmânt mic dejun 2008 Conferinta la Colegiul American de radiaþii oncologie reuniuni anuale - Sirtex Sponsors Educational Breakfast Lecture At The 2008 American College Of Radiation Oncology Annual Meeting - articole medicale engleza - startsanatate